Title
Category
Credits
Event date
Cost
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.
  • Bipolar Disorder
  • Posttraumatic Stress Disorder
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$10.00
For patients who have PTSD and also have a severe mental illness, can psychotherapies for PTSD still be effective? If so, what component might offer greater efficacy?
  • Attention-Deficit/Hyperactivity Disorder
  • Autism Spectrum Disorders
  • Bipolar Disorder
  • Child and Adolescent Psychiatry
  • Depression
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Women’s Mental Health
  • AMA PRA Category 1 Credit™
  • Participation
$10.00
Is there an association between postpartum depression or psychosis and subsequent disorders in either the mother or the child who is exposed to postpartum maternal illness?
  • Antipsychotics
  • Bipolar Disorder
  • Dementia
  • Diagnostic Tools
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Can you recognize risk factors for tardive dyskinesia? Are you familiar with diagnostic criteria? Do you regularly assess patients for the condition? Are you knowledgeable about using new medications for TD? Experts share best practices for the assessment and treatment of TD.
  • Antipsychotics
  • Diagnostic Tools
  • Movement Disorders
  • Patient/Physician Communication
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Although clinicians are pressed for time, diligence in assessing for tardive dyskinesia in patients taking antipsychotics is crucial, especially now that treatment is available. In this brief CME activity, Dr Nierenberg describes the evaluation process. 
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • Treatment Resistance
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Two experts offer a refresher on predictors and identification of treatment-resistant schizophrenia. Drs Correll and Howes also review therapeutic strategies.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Diagnostic Tools
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients may be more willing to accept some adverse effects than others. Dr Kane offers advice on addressing side effects that prevent patients from maintaining their medication adherence.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotherapy
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Can a patient-centered approach to treatment be adopted for patients with schizophrenia? Can these patients take part in shared decision-making? Follow along as Dr Harvey shares his expertise.

Pages